Of note, the sequelae of stroke, including paralysis, depression, speech disturbance, and visual disturbance, remain in ≈75% of stroke survivors.[2] Although thrombolytic therapy with tissue plasminogen activator and endovascular thrombectomy for acute ischemic stroke are available with a short therapeutic window,[3] more than 1000 new drugs clinical trials have failed to develop safe and effective therapies for stroke. The gene discussed is PLAT; the disease is stroke disorder.